Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 78

  • 3 898 clinical trials
  • 1 548 recruiting
  • 703 conditions
  • 31 countries

Conditions in this area

703 conditions with trials, the busiest first

Non-small cell lung cancer327Breast cancer168Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic105Prostate cancer101Ovarian cancer91Colorectal cancer89Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Malignant melanoma79Chronic lymphocytic leukaemia77Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV57Pancreatic carcinoma57Hormone-refractory prostate cancer56Gastric cancer55Bladder cancer54Endometrial cancer53+679

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 898 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 898 clinical trials

Glioma

Recruiting

Study of Temozolomide and Lomustine Followed by Radiotherapy versus Standard Treatment in Patients with Newly Diagnosed Grade 2 or 3 Glioma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lomustine
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Acute lymphocytic leukaemia recurrent+1

Recruiting

Study on CD19+ Lymphoid Disease Using Genetically Modified T Cells for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:T Lymphocytes Transduced With A Rv-Sfg.cd19.Cd28.4-1Bbzeta Retroviral Vector
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Endometrial sarcoma

Recruiting

Study on Stopping or Continuing Anastrozole, Letrozole, and Exemestane for Patients with Advanced or Metastatic Low-Grade Endometrial Stromal Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:Centre Leon Berard

Malignant melanoma stage IV+1

Recruiting

Study of Regorafenib with BRAF/MEK-Inhibitor Combination for Patients with Advanced Melanoma After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Regorafenib
  • Sponsor:UZ Brussel

Pleural mesothelioma malignant

Recruiting

Study of Intrapleural Photodynamic Therapy with Aminolevulinic Acid Hydrochloride and Nivolumab for Patients with Malignant Pleural Mesothelioma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Centre Hospitalier Universitaire De Lille

Paget's disease of the vulva

Recruiting

Study on the Use of Methyl Aminolevulinate and PAGETEX Device for Treating Vulvar Extra-Mammary Paget's Disease in Women

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methyl Aminolevulinate
  • Sponsor:Centre Hospitalier Universitaire De Lille

Central nervous system lymphoma+4

Recruiting

Study on Golcadomide and Valemetostat Tosylate for Patients with Relapsed or Refractory Non-Hodgkin Lymphomas

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Golcadomide
  • Sponsor:Celgene Corp.

Small cell lung cancer extensive stage

Recruiting

Study on Maintenance Therapy with Durvalumab and Olaparib for Patients with Extensive Disease Small-Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University Of Cologne

Neuroblastoma

Recruiting

Study Comparing [18F]meta-fluorobenzylguanidine PET-CT and Iodine (123I) Iobenguane Scans for Detecting Neuroblastoma in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:[18F]Meta-Fluorobenzylguanidine
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Plasma cell myeloma+1

Recruiting

Study of Selinexor, Dexamethasone, and Bortezomib for Patients with Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Karyopharm Therapeutics Inc.

Pseudomyxoma peritonei

Recruiting

Study on Capecitabine and Cyclophosphamide for Patients with Large Pseudomyxoma Peritonei Preparing for Surgery and Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Rectal cancer

Recruiting

Study on Capecitabine and Oxaliplatin for High-Risk Rectal Cancer Patients to Reduce Metastases

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:HUS-Yhtymae

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab462 clinical trialsCarboplatin340 clinical trialsCisplatin285 clinical trialsPaclitaxel263 clinical trialsFluorouracil237 clinical trialsOxaliplatin227 clinical trialsNivolumab217 clinical trialsDexamethasone169 clinical trialsBevacizumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.